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Abstract: Pulmonary arterial hypertension (PAH) is a devastating disease characterized by 
progressive elevation of pulmonary arterial pressure and vascular resistance due to pulmonary 
vasoconstriction and vessel remodeling as well as inflammation. Rho-kinases (ROCKs) are one 
of the best-described effectors of the small G-protein RhoA, and ROCKs are involved in a variety 
of cellular functions including muscle cell contraction, proliferation and vascular inflammation 
through inhibition of myosin light chain phosphatase and activation of downstream mediators. 
A plethora of evidence in animal models suggests that heightened RhoA/ROCK signaling is 
important in the pathogenesis of pulmonary hypertension by causing enhanced constriction 
and remodeling of the pulmonary vasculature. Both animal and clinical studies suggest that 
ROCK inhibitors are effective for treatment of severe PAH with minimal risk, which supports 
the premise that ROCKs are important therapeutic targets in pulmonary hypertension and that 
ROCK inhibitors are a promising new class of drugs for this devastating disease.
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Pulmonary hypertension
Pulmonary arterial hypertension (PAH), characterized by an elevated, sustained 
increase in pulmonary artery pressure greater than 25 mmHg at rest or 30 mmHg upon 
exertion, is a progressive disease with poor prognosis and death usually occurring 
within 5 years if left untreated.1 Further, primary or idiopathic pulmonary hypertension 
(IPAH) can result in death within a median of 3 years from right ventricular failure 
without treatment, with a 15% 1-year mortality rate despite current therapy.2 Factors 
contributing to PAH include prolonged vasoconstriction, vascular remodeling, inflam-
matory cell migration, and in situ thrombosis which result in the formation of vascular 
lesions.3,4 It is currently thought that the primary cause of the elevated pulmonary 
vascular resistance that occurs in PAH is due to mechanical obstruction from vascular 
remodeling.5,6 In addition, pathologic findings show that PAH is associated with intimal 
and/or medial hypertrophy, intimal fibrosis, and plexiform lesions.7
Animal models of pulmonary hypertension
Although the long-term prognosis for patients with PAH is rather poor, recent advances 
in the understanding of pathophysiological mechanisms underlying the progression of 
PAH have been made possible through the use of experimental animal models. The 
monocrotaline model of PAH, initially used over 40 years ago, is induced via a single 
injection of 60 mg/kg monocrotaline either intraperitoneally or subcutaneously.8 Rapid 
and severe pulmonary vascular disease usually occurs within a few days (independent of Vascular Health and Risk Management 2009:5 664
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any cardiac or lung parenchymal disorders), suggesting that 
this model is an excellent choice to study IPAH. Although the 
basic underlying mechanism of monocrotaline-induced PAH 
is not well understood, it is known that the parent compound 
is not toxic, and must be activated to the reactive monocrota-
line pyrrole by hepatic cytochrome P450 3A, which targets 
the pulmonary vascular endothelium.9–12 A limitation of this 
experimental model is that differences exist in monocrotaline 
sensitivity between rat strains as well as individual variances 
in the pharmacokinetics of monocrotaline involving degra-
dation and hepatic formation of the pyrrole or conjugation 
and excretion.13
A second widely employed model of PAH is the use of 
chronic hypoxia. Studies show that decreasing the alveolar 
oxygen pressure to 70 mmHg elicits a strong pulmonary 
vasoconstrictor response; however, the hypoxic-induced 
effect varies among animal species.14 For example, rabbits 
show very little response to alveolar hypoxia, but cattle 
exhibit the greatest vasoconstriction, and hypoxic pulmonary 
vasoconstriction is milder in humans than in rats.15 Further, 
the hypoxic pulmonary vasoconstrictor response varies 
among humans.16 The time of exposure to hypoxia appears 
to be critical as short exposure causes acute pulmonary 
vasoconstriction, while prolonged hypoxia results in remod-
eling of the distal pulmonary arterial branches. It has also 
been observed that endothelial and smooth muscle hyperpla-
sia occurs in the walls of pulmonary arteries in rats during 
the first days of hypoxic exposure.17,18 In animal models, 
intermittent severe hypoxia leads to the development of 
PAH, independent of the duration of the hypoxia to normoxia 
intervals. However, in humans, intermittent hypoxia elicits 
only a small clinically irrelevant effect on pulmonary 
hemodynamics.19 Thus, caution must be exercised when 
extrapolating animal models of chronic hypoxic-induced 
PAH to the human setting. Another documented animal 
model of PAH involves the formation of chronic emboli in 
pulmonary vessels. Shelub et al induced chronic embolic 
PAH through repeated microembolizations with the injection 
of Sephadex® microspheres.20 The utilization of this approach 
allows different-sized vessels to be targeted depending on 
the diameter size of the microspheres that are injected, and 
vascular obstruction and vasoconstriction are the primary 
mechanisms of the high pulmonary vascular resistance that 
occurs.20,21 More recently, repeated embolizations with poly-
dextran microspheres were used in pigs to elicit a sustained 
elevation in pulmonary arterial pressure.22
A recent rat animal model of experimental PAH described 
by Taraseviciene-Stewart and colleagues involves the 
combination of vascular endothelial growth factor receptor 
blockade with SUGEN (SU) 5416 and chronic hypoxia 
exposure.23 A severe, progressive PAH occurs which is 
accompanied by precapillary arterial occlusion by proliferat-
ing factor VIII-positive endothelial cells. In addition, the PAH 
in these animals is resistant to treatment with drugs that are 
commonly used to treat human PAH.24 Thus, it appears that 
this particular model of PAH more closely mimics human 
severe PAH than the monocrotaline and chronic hypoxia 
models of PAH which can be successfully treated with a 
variety of agents.25 Finally, the newest animal models of PAH 
involve the use of genetically modified animals as genetic 
screening has identified a number of potentially important 
gene variants that may contribute towards the development 
of PAH. For example, since a heterozygous mutation of the 
BMPR2 gene which encodes for the bone morphogenetic 
protein receptor-II is present in a large portion of patients 
with IPAH, heterozygous BMPR2-deficient mice have been 
used to mimic the human condition with limited success.26–28 
Further, serotonin (5-HT), and its plasma membrane trans-
porter (5-TTT) has been reported to be involved in the patho-
genesis of PAH in humans, and genetically engineered mice 
lacking the 5-HTTT exhibit attenuated hypoxia-induced PAH, 
and mice overexpressing 5-HTTT can cause PAH.29,30
Current therapies for pulmonary 
hypertension
Although there is a variety of drugs that are currently used or 
under investigation for the treatment of PAH, there is no spe-
cific drug class that is completely efficacious in reversing the 
deleterious effects of this disease. Nitric oxide (NO) has been 
used with mixed success as a therapy for PAH. Exogenous 
administration of the inhaled preparation of NO reduces 
pulmonary vascular resistance without having an effect on 
systemic vascular resistance or cardiac function.31,32 Inhaled 
NO has been used to treat primary pulmonary hypertension, 
secondary pulmonary hypertension in association with 
congenital or acquired heart disease, chronic obstructive 
pulmonary disease (COPD), and Adult Respiratory Distress 
Syndrome (ARDS).33–35 Evidence suggests that the efficacy of 
NO is dependent on the inhaled concentration. For example, 
it has been observed that 40 ppm inhaled NO will reverse 
hypoxic pulmonary vasoconstriction in healthy individuals 
independent of systemic effects, and initial results showed 
improvement in ARDS patients.36,37 However, it was also 
reported that inhaled NO in doses greater than 10 ppm worsen 
arterial oxygenation and therefore, it was suggested that 
lower doses be used to treat ARDS.38 The primary limiting Vascular Health and Risk Management 2009:5 665
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factor in the global use of inhaled NO is the potential toxicity 
that may occur if high concentrations are used. Chemical 
reactions with oxygen and reactive oxygen species yield 
toxic nitrogen oxides and hydroxyl radicals. Subsequently, 
nitrogen oxide reacts with superoxide to form peroxynitrite, 
which can elicit pulmonary cellular injury.39
The prostanoids are another class of agents used to treat 
PAH as these substances have been successfully tested in 
animal models of PAH, and prostacyclin and its analogs 
have been extensively studied in the treatment of human 
PAH.40,41 Mechanistically, prostacyclin exerts vasoprotec-
tive effects through pulmonary vasodilatation, inhibition of 
platelet aggregation, and pulmonary arterial smooth muscle 
proliferation.42 Because of prostacyclin’s short half-life, 
several analogs have been developed which appear to exhibit 
long-term beneficial vasodilatory and antithrombotic effects 
in patients with PAH when given by daily inhalation.43 
Specifically, aerosolized iloprost causes selective pulmonary 
vasodilation in patients with either primary or secondary 
pulmonary hypertension.43 In contrast, beraprost has limited 
effectiveness in treating both primary and secondary PAH.44,45 
Most recently, it was found that intravenous epoprostenol 
improves survival in patients with PAH.46
Endothelin (ET) receptor antagonists represent some of 
the newest class of agents available for treatment of PAH. 
The selective ETA receptor antagonist BQ-123 was the first 
ET receptor antagonist to exhibit beneficial effects in animal 
models of PAH, and bosentan, an antagonist of both ETA 
and ETB receptors reduces the medial thickening and neo-
muscularization of pulmonary arteries as well as lowering 
pulmonary arterial pressure in rat animal models of PAH.47–49 
Studies also show that bosentan is clinically effective in 
patients with PAH, which included significant improve-
ment in exercise capacity, functional class, and pulmonary 
hemodynamics.50,51
The newest and most potentially efficacious therapeutic 
agents to date are the phosphodiesterase (PDE) 5 inhibitors, 
which were discovered incidentally to have pulmonary 
vasodilating effects in addition to being used to treat erec-
tile dysfunction. Sildenafil attenuates the acute pulmonary 
vasoconstrictor response to hypoxia in humans as well as 
lowering high-altitude-induced temporary PAH in healthy 
volunteers.52,53 In addition, sildenafil decreases RV mass in 
patients with PAH, suggesting that PDE5 inhibitors may 
be able to reverse the RV remodeling that occurs in PAH.54 
Further, the combination of sildenafil and besaprost may be 
efficacious in treating PAH.55 Other therapies include adre-
nomedullin, an endogenously produced vasodilator originally 
discovered in human pheochromocytoma, and levosimendan, 
a dual calcium-sensitizing positive inotropic agent and potas-
sium channel activator. Inhaled adrenomedullin may improve 
exercise capacity and selectively decrease pulmonary vascu-
lar pressure in patients with primary pulmonary hypertension, 
and intravenous levosimendan significantly lowers pulmo-
nary vascular resistance after heart transplant procedure.56,57 
Finally, calcium channel blockers have been used with 
limited success as less than 10% of patients with PAH have 
a beneficial acute pulmonary vasodilatory response to long-
term treatment.58 Mechanisms by which currently used drugs 
elicit pulmonary vasodilatation for treatment of pulmonary 
hypertension are shown in Figure 1, although the limited 
success of these current therapeutic regimens has been the 
impetus for investigating the feasibility of therapeutically 
targeting Rho-kinase signaling mechanisms in PAH.
Rho-kinase
There is convincing evidence that Rho-kinases are involved 
in a variety of cardiovascular diseases including pulmonary 
hypertension.59–64 Approximately seventeen years ago it was 
revealed that a small monomeric GTPase called Rho induced 
the formation of stress fibers and focal adhesions in 3T3 
cells.65 Subsequently, a number of laboratories demonstrated 
that Rho was expressed in smooth muscle and could be acti-
vated by a plethora of contractile agonists.66 Although Rho 
was shown to increase Ca2+ sensitivity and phosphorylate 
myosin light chain in intact smooth muscle, these events 
could not occur in permeabilized smooth muscle cells, sug-
gesting that activation required interaction of Rho with a 
second component of the plasma membrane.67,68
In the mid 1990s a number of investigators working 
independently identified one of the effectors of Rho and 
termed it Rho-kinase, and it was postulated that this was the 
component necessary for Rho activation.69,70 In 1996, it was 
reported that Rho-kinase (ROCK) was activated by Rho, 
which subsequently phosphorylated and inhibited myosin 
light chain phosphatase.71 One year later it was found that 
translocation of Rho to the plasma membrane was neces-
sary for increasing Ca2+ sensitivity.72 Further, it was widely 
documented that Rho and/or ROCK antagonists inhibited 
the effect of contractile agonists indicating that both Rho 
and ROCK were major effectors of agonist-induced Ca2+ 
sensitization in smooth muscle.67,73–75 ROCKs are serine/
threonine kinases with a molecular mass of approximately 
160 kDa.1,61 These kinases are expressed in invertebrates such 
as Caenorhabditis elegans, Drosophila, and mosquito, and 
in vertebrates such as zebrafish, Xenopus, chicken, mouse, Vascular Health and Risk Management 2009:5 666
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rat, and human.61 ROCK’s catalytic site is adjacent to its 
NH2 terminus, whereas the Rho binding site is located at the 
COOH-terminal portion of its coiled-coil domain.66 ROCKs 
regulate a variety of cellular functions including motility, 
proliferation, apoptosis, contraction, and gene expression, 
and are believed to be the most important regulators of 
Ca2+ sensitivity in smooth muscle.61,66,76,77 ROCK-mediated 
pathophysiological mechanisms that may contribute to the 
development of pulmonary hypertension are summarized 
in Figure 2.
Currently, two isoforms (ROCK-1 and ROCK-2) have 
been identified, which are expressed in vascular smooth 
muscle.61 ROCK activation increases the Ca2+ sensitivity 
of contraction in vascular smooth muscle via inhibition 
of myosin light chain phosphatase, which increases the 
phosphorylation of myosin light chain and augments 
contraction at any given level of cytosolic Ca2+ and activity 
of myosin light chain kinase.78 ROCK inhibits myosin 
light chain phosphatase by phosphorylating the 130 kDa 
myosin-binding subunit myosin light chain phosphatase 
(MYPT-1) and/or the myosin light chain phosphatase 
inhibitor protein CPI-17.66 Further, ROCKs target other 
substrates that are important for smooth muscle contraction 
such as calponin.61
RhoA activates ROCK after extracellular G-protein 
coupled receptor binding.72 Depending on the agonist 
stimulation, ROCK may increase Ca2+ sensitivity of the 
contractile apparatus via phosphorylation of MYPT-1 at 
threonine (Thr)-696 and Thr-853, and phosphorylation of 
CPI-17 at Thr-38.66 More recently, it was shown that ROCK 
also phosphorylates Thr-855 on MYPT-1.79,80
Rho-kinases as targets 
for pulmonary hypertension
Evidence strongly suggests that RhoA/ROCK is an attractive 
target for the development of therapeutics to treat PAH as 
many studies have shown that ROCK signaling is involved in 
the sustained vasoconstriction and vascular remodeling and 
Figure 1 Mechanisms through which current drugs elicit pulmonary vasodilatation to treat pulmonary hypertension.
Abbreviations: eT-1, endothelin-1; CCBs, calcium channel blockers; PGi2, prostacyclin; NO, nitric oxide; CaM, calmodulin; SR, sarcoplasmic reticulum; AC, adenylate cyclase; 
MLCK, myosin light chain kinase; MLCPh, myosin light chain phosphatase, PDe5, phosphodiesterase 5; PLC, phospholipase C; sGC, soluble guanylate cyclase.
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inflammation that occurs in this disease. Oka et al reported 
that ROCK signaling mediated vasoconstriction in severe 
occlusive pulmonary hypertension in rats, and other studies 
have shown that ROCKs are involved in hypoxic pulmonary 
vasoconstriction, hypoxic pulmonary hypertension, and 
monocrotaline-induced pulmonary hypertension.3,81–83 More 
recently, studies confirmed that ROCK-mediated prolonged 
vasoconstriction was inherently involved in chronic hypoxic 
pulmonary hypertension in both neonatal and adult rats as 
well as in bleomycin-induced pulmonary hypertension.84,85 
Endothelin-1 increases pulmonary vasoconstriction via 
ROCK signaling, and small pulmonary arteries exhibit 
ROCK-dependent increases in myogenic tone in chronic 
hypoxic pulmonary hypertension.86–88 Further, ROCKs have 
been implicated in the vascular remodeling associated with 
experimental models of PAH, and a recent report by Guilluy 
and colleagues suggests that transglutaminase-mediated 
activation of RhoA by serotonin may be involved in 
pulmonary vascular remodeling induced by chronic 
hypoxia.78,89–91 In humans, preliminary studies show that the 
pulmonary vasodilatory response in hypertensive pulmonary 
arteries and isolated perfused lung lobes removed from lung 
transplantation patients for severe PAH is associated with 
high RhoA/ROCK activity.92
Studies involving ROCK inhibitors have been primarily 
done with either fasudil or Y-27632. Both compounds are 
cell-permeable and potently inhibit ROCK in vascular 
smooth muscle.93,94 Fasudil, initially described as an 
intracellular calcium antagonist, is a selective inhibitor of 
ROCK.61,74,95 Specifically, fasudil is metabolized in the liver 
to the active compound hydroxyfasudil, which is a specific 
ROCK inhibitor because its efficacy for ROCK is 100-fold 
higher than for protein kinase C (PKC), and 1000-fold higher 
than for myosin light chain kinase.93,96 Similarly, Y-27632, 
a pyridine derivative, binds to and inhibits p160ROCK up 
to 200-fold higher than PKC or PKA.74
The mechanisms by which ROCK antagonists attenuate 
PAH are widespread. Evidence from in vivo studies suggests 
that the effect of ROCK inhibitors is associated with 
decreased pulmonary artery expression of growth factors and 
markers of cell proliferation, matrix protein production, and 
inflammatory cell infiltration as well as an increase in signals 
for apoptosis.97 In vitro studies also suggest a negating effect 
of ROCK inhibitors on pulmonary vascular cell growth. 
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Figure 2 Schematic illustration of possible Rho-kinase mediated pathophysiological mechanisms that may contribute to the development of pulmonary hypertension.
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Chapados and colleagues reported that Y-27632 prevented 
stress fiber formation and reduced nuclear extracellular 
signal-regulated kinase and tenascin-C expression.98 
In animal models of PAH, fasudil or Y-27632 decreases the 
sustained vasoconstrictor response and vascular remodeling 
that occurs during exposure to monocrotaline or hypoxia.78,99 
Further, inhibition of ROCK attenuates pulmonary arterial 
pressure and reverses pulmonary vasoconstriction caused by 
NO synthase (NOS) antagonists in chronically hypoxic lungs, 
and ROCK antagonists also lower acute hypoxia-mediated 
contraction of isolated rat pulmonary artery segments and 
isolated mouse lungs.77,78,83 Oka et al also showed that this 
same compound acutely lowered right ventricular systolic 
pressure in SU5416/hypoxia-exposed rat lungs.3 In mouse 
models of PAH, treatment with Y-27632 decreased the 
muscularization of distal pulmonary arteries and upregulated 
eNOS expression, and Abe and colleagues observed that 
inhibiting chronic hypoxic PAH in mice increased lung eNOS 
expression and Akt phosphorylation.78,100
Finally, evidence suggests that statins may also be 
effective inhibitors of ROCK. Statins (HMG-CoA reductase 
inhibitors) block the synthesis of mevalonate and its 
isoprenoid intermediate compound geranylgeranylpyrophos-
phate, which subsequently inhibits isoprenylation of RhoA 
and its translocation to the plasma membrane.101 Statins ame-
liorate PAH in a variety of rat models, and a recent report by 
Girgis et al provides evidence that reversal of hypoxic PAH 
by simvastatin is coupled to decreased lung expression and 
activity of both ROCK I and II.24,102–107 In addition, Li et al 
observed that atorvastatin blocked serotonergic-mediated 
pulmonary artery smooth muscle proliferation and migration 
by inhibiting membrane translocation of RhoA.108
Rho-kinase inhibitors as therapies 
for pulmonary hypertension
ROCK inhibitors have been used for approximately 15 years 
to treat cardiovascular disorders including vasospasm after 
subarachnoid hemorrhage and stable effort angina pectoris 
with no adverse effects.61,95 Although relatively few, clinical 
studies with ROCK inhibitors also show that fasudil is an 
effective treatment for severe pulmonary hypertension. 
In PAH patients that did not respond to oxygen inhalation, 
NO inhalation, or nifedipine, 30-minute intravenous fasudil 
treatment significantly decreased elevated pulmonary 
vascular resistance without causing systemic hypotension.63 
Further, Ishikura et al confirmed that fasudil had acute benefi-
cial pulmonary hemodynamic effects in patients with PAH.109 
Collectively, these clinical studies suggest that ROCK 
signaling is a viable therapeutic target as a treatment for 
pulmonary hypertension with ROCK inhibitors (Figure 1). 
However, although fasudil appears to be a promising agent 
to use for PAH, long-term effects of fasudil administration 
in patients with severe pulmonary hypertension need to be 
evaluated before more definitive conclusions can be made as 
to the efficacy of this type of agent. Studies also suggest that 
this drug can be used for other cardiovascular diseases with 
minimal side effects. Oral treatment with fasudil for at least 
4 weeks significantly lengthened maximum exercise time 
without any effect on blood pressure and heart rate during 
the exercise independent of any serious unwanted side effects 
from the drug.61 In addition, fasudil improved myocardial 
ischemia in patients with microvascular angina caused by 
coronary microvascular vasoconstriction.110
Conclusions
One of the biggest obstacles in treating pulmonary 
hypertension is identifying effective therapeutic agents that 
selectively target the pulmonary vasculature with minimal 
side effects. The RhoA/ROCK signaling pathway is an 
important regulator of pulmonary vascular function and 
animal studies have shown that this pathway is important in 
the pathogenesis of major disease states such as pulmonary 
hypertension. Further studies should be done to determine 
how ROCKs mediate pulmonary vascular smooth muscle 
cell physiology and how these moieties are involved in 
vascular disease states. Recent clinical studies in humans 
show promise in that acute treatment with ROCK inhibitors 
in patients with severe pulmonary hypertension exhibited 
signs of improved pulmonary vascular function by attenu-
ating the ROCK-mediated increase in pulmonary vascular 
resistance. Towards this end, large clinical trials are the 
logical next step in demonstrating that long-term treatment 
with ROCK inhibitors is both safe and efficacious in patients 
with pulmonary hypertension.
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